RJA
CGTX icon

Raymond James & Associates’s Cognition Therapeutics CGTX Stock Holding History

Raymond James & Associates’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$4.69K Hold
10,000
– – ﹤0.01% 3983
2024
Q2 		$16.6K Hold
10,000
– – ﹤0.01% 3907
2024
Q1 		$18.2K Buy
+10,000
New +$20.6K ﹤0.01% 3876

Other funds holding CGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Raymond James & Associates's CGTX Position: Q3 2024 in Review

Raymond James & Associates held its Cognition Therapeutics (CGTX) position steady in Q3 2024 at 10,000 shares worth $4.69K. The position accounts for ﹤0.01% of the portfolio, ranked #3983.

Raymond James & Associates first reported a position in CGTX in Q1 2024 and has held it in 3 quarters since. The position peaked at $18.2K in Q1 2024. 40 funds tracked by Wall St. Rank hold CGTX as of Q3 2024.

  • Raymond James & Associates held 10,000 shares of Cognition Therapeutics worth $4.69K as of Q3 2024.
  • Raymond James & Associates left its Cognition Therapeutics share count unchanged in Q3 2024.
  • Cognition Therapeutics made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3983 holding.
  • Raymond James & Associates first reported a position in Cognition Therapeutics in Q1 2024 and has held it in 3 quarters since.
  • Raymond James & Associates's Cognition Therapeutics position peaked at $18.2K in Q1 2024.
  • 40 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.